ArQule, Inc. (NASDAQ:ARQL)

CAPS Rating: 4 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.


Player Avatar zzlangerhans (99.80) Submitted: 2/25/2013 6:47:13 AM : Outperform Start Price: $2.40 ARQL Score: -77.50

ArQule has fallen off the oncology A-list after the failure of tivatinib in phase III trials for NSCLC, but the company has a solid cash runway and a controlled burn due to strong partnership deals. The stock has been in decline despite the beginning of enrollment in the phase III trial of tivatinib in hepatocellular carcinoma. Burned traders could be forgiven for wanting to give ArQule a pass this time around, but eventually the street will notice the low enterprise value for a progressing phase III oncology trial. Even a small chance at success in a subpopulation is worth more than what ArQule is being spotted now.

Featured Broker Partners